Healthcare / Diagnostics & ResearchStockholm
$0.49
+0.02 (+4.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-9.2M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$112M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-8.2%
↓Gross Margin
52.2%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.8%
FCF CAGR
—
FCF margin
-17.2%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $53.1M · net income $-12.2M · FCF $-9.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $53.1M | $53.1M | $57.4M | $43.0M | $37.0M |
| Net Income | $-12.2M | $-12.2M | $-3.3M | $-59.3M | $-59.0M |
| EBITDA | $-8.1M | $-8.1M | $3.1M | $-13.7M | $-12.1M |
| EPS | -0.05 | -0.05 | -0.01 | -0.26 | -0.28 |
| Gross Margin | 52.2% | 52.2% | 54.9% | -4.9% | -5.7% |
| Operating Margin | -20.2% | -20.2% | -9.1% | -139.4% | -162.6% |
| Net Margin | -22.9% | -22.9% | -5.8% | -137.8% | -159.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.10 | 0.11 | — |
| Current Ratio | 3.49 | 3.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.2M | $-9.2M | $-2.9M | $-14.7M | $-17.8M |
| Returns | |||||
| ROE | -8.2% | -8.2% | -2.1% | -36.2% | -26.5% |
| Valuation | |||||
| P/B | 0.77 | 0.77 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -7.5% | -7.5% | 33.5% | 16.4% | — |
| EPS Growth | -400.0% | -400.0% | 96.2% | 7.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.05
Residual
-14.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.